Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1842 2
1950 1
1951 3
1964 1
1966 1
1993 1
1997 1
1999 2
2000 4
2001 5
2002 6
2003 7
2004 2
2005 10
2006 11
2007 10
2008 11
2009 11
2010 17
2011 15
2012 16
2013 7
2014 18
2015 20
2016 8
2017 14
2018 24
2019 28
2020 20
2021 18
2022 11
Text availability
Article attribute
Article type
Publication date

Search Results

269 results
Results by year
Filters applied: . Clear all
Page 1
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D. Smolen JS, et al. Among authors: edwards cj. Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22. Ann Rheum Dis. 2020. PMID: 31969328 Free article.
Lupus, vaccinations and COVID-19: What we know now.
Mason A, Anver H, Lwin M, Holroyd C, Faust SN, Edwards CJ. Mason A, et al. Among authors: edwards cj. Lupus. 2021 Sep;30(10):1541-1552. doi: 10.1177/09612033211024355. Epub 2021 Jun 17. Lupus. 2021. PMID: 34134555 Review.
Upadacitinib for the treatment of rheumatoid arthritis.
Serhal L, Edwards CJ. Serhal L, et al. Among authors: edwards cj. Expert Rev Clin Immunol. 2019 Jan;15(1):13-25. doi: 10.1080/1744666X.2019.1544892. Epub 2018 Nov 19. Expert Rev Clin Immunol. 2019. PMID: 30394138 Review.
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Cañete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C; R4RA collaborative group. Humby F, et al. Among authors: edwards cj. Lancet. 2021 Jan 23;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2. Lancet. 2021. PMID: 33485455 Free PMC article. Clinical Trial.
Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial.
Shipa M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, Isenberg DA, Doré CJ, Gordon C, Ehrenstein MR; BEAT-LUPUS Investigators, D'Cruz DP, Jordan N, Parker B, Lightstone L, Salama A, Pyne D, Edwards CJ, Griffiths B, Vital EM, Rhodes B, Yee CS, Akil M, Topham P, Gullick NJ. Shipa M, et al. Among authors: edwards cj. Ann Intern Med. 2021 Dec;174(12):1647-1657. doi: 10.7326/M21-2078. Epub 2021 Oct 26. Ann Intern Med. 2021. PMID: 34698499 Clinical Trial.
Biosimilars.
Edwards CJ, Bellinvia S. Edwards CJ, et al. Lupus. 2020 May;29(6):525-532. doi: 10.1177/0961203320910797. Epub 2020 Mar 18. Lupus. 2020. PMID: 32188301 Review. No abstract available.
269 results